<DOC>
	<DOCNO>NCT01618929</DOCNO>
	<brief_summary>- To search effect montelukast airway inflammation include FEV1 % , FEV1 % /FVC , provocholine® ( methacoline chloride powder inhalation ) challenge test , leukotriene level exhale breath condensate asthmatic child without food allergy age 6-18 year old . - To define patient group good response montelukast define parameter predict good response .</brief_summary>
	<brief_title>Effects Montelukast Asthmatic Children With Without Food Allergy</brief_title>
	<detailed_description>The aim analysis determine whether child food allergy may eosinophilic inflammation airway ( measure FENO ) may Cysteinyl leukotrienes base inflammation airway show high level Cys LT low level lipoxin exhale breath condensate . Our suggestion special pattern inflammation may see asthmatic food allergy strong atopic march history aim test montelukast effective child ratio Cysteinyl LT inflammation high relative FENO ( eosinophilic inflammation ) . This study first evaluate effect montelukast regard synthesis Cys leukotrienes , lipoxin FENO measure exhaled breath condensate , mirror local inflammation airways asthmatic child atopy ( food allergy ) . As mentioned another factor plan analyze ratio Cys leukotriene lipoxin , natural antagonist LT . This study determine ratio Cyst LT lipoxin Cyst LT FENO exhale breath condensate analysis see correlation inflammatory marker montelukast related change FEV1 % , FEV1 % /FVC .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Food Hypersensitivity</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Physician diagnose asthma ( 12 % reversibility spirometry test positive response provocholine® provocation test ) . Mild moderate asthmatic child . Asthmatic child prebudesonide FEV1/FVC ≥ 80 % include . At least one food allergy confirm specific IgE level skin prick test positivity relevant clinical history open challenge test food . Aged 618 year old . Acceptance involvement study sign inform consent ( Both patient one parent ) Who sign inform consent . Severe asthmatic child Any lung disease except asthma ( i.e . cystic fibrosis , bronchiectasia , primary ciliary dyskinesia ) . Any systemic disease except allergic rhinitis atopic dermatitis Followup intensive care unit intubation asthma exacerbation within one year . Attendance emergency room hospital admission within 3 month asthma exacerbation Systemic steroid usage within 3 month Upper airway infection within one month . Psychiatric psychosocial problem Poor compliance asthma treatment protocol Any condition contraindicate montelukast usage To aware name drug either patient study staff study period . Worsening clinical condition runin period . Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Food allergy</keyword>
	<keyword>Asthma</keyword>
	<keyword>Children</keyword>
	<keyword>Montelukast</keyword>
	<keyword>Inflammation</keyword>
</DOC>